Clinical Trial Update: Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma [Phase 4]

View source ↗

Summary

Phase 4 trial investigating prophylactic Baraclude (Entecavir) to prevent hepatitis B reactivation in patients who are HBsAg negative/HBcAb positive/HBV DNA neg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Lymphoma

Drugs mentioned

• Baraclude (Entecavir) (Entecavir)

Snippet

Sponsor: Peking University | Conditions: Hepatitis B | Phase 4 | Status: UNKNOWN